AI-Derived ECG Age Gap as a Digital Biomarker for Cardiovascular Risk Stratification

Shun Huang[1,†], GuangKun Nie[1,2,†], Donglin Xie[1,3], Jun Li[1], Gongzheng Tang[1,3], Deyun Zhang[4], Qi Xu[5], and Shenda Hong[1,3,*,©]

[1]National Institute of Health Data Science, Peking University, Beijing, China
[2]School of Intelligence Science and Technology, Peking University, Beijing, China
[3]Institute of Medical Technology, Peking University Health Science Center, Beijing, China
[4]Heart Voice Medical Technology, Hefei, China
[5]Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida.
*Correspondence: hongshenda@pku.edu.cn

ABSTRACT

Cardiovascular diseases remain the leading cause of global mortality, and early risk stratification is critical for improving prognosis. Artificial intelligence–derived electrocardiography (AI-ECG) provides a promising approach to derive cardiac biological age as a non-invasive digital biomarker. This study developed an AI-ECG framework based on the ECGFounder foundation model to quantify cardiac biological aging and predict cardiovascular risk. A total of 67,824 ECGs from 63,512 UK Biobank participants were included. The model was trained on the development cohort (n = 26,871),comprising healthy individuals, and evaluated in an independent clinical evaluation cohort (n = 40,953). The AI-ECG Age Gap was assessed for its association with MACCE and other secondary outcomes using Cox models. The model demonstrated good agreement between predicted and chronological age in the development cohort (r = 0.646; MAE = 4.61 years). In the clinical cohort, after adjusting for clinical comorbidities, each 1-year increase in the age gap was associated with a significant 13% higher risk of (HR = 1.13, 95% CI: 1.11–1.14) Individuals with an overestimated age gap (> 6 years) exhibited substantially elevated risks of MACCE (HR 4.51) and other major cardiovascular outcomes, whereas those with an underestimated age gap (< -6 years) showed a significantly lower risk of MACCE (HR 0.46) alongside protective effects across other outcomes. The AI-ECG age gap effectively quantifies occult accelerated cardiac aging. As a non-invasive digital biomarker, it exhibits immense potential for cardiovascular risk stratification in broad populations.

INTRODUCTION

Cardiovascular diseases (CVDs) remain the leading cause of mortality and reduced quality of life worldwide[1,2]. According to World Health Organization (WHO) data, approximately 19.8 million people globally died from CVDs in 2022, accounting for about 32% of all global deaths[3], posing a continuous and severe challenge to public health systems[4]. Although early risk identification and timely intervention are crucial for improving patient prognosis, traditional clinical screening methods are often limited access to medical resources or rely on overt pathological features[5–7]. As an essential diagnostic tool for CVDs, the electrocardiogram (ECG) has become an ideal initial screening instrument due to its advantages of low cost, non-invasiveness, and high accessibility[8]. However, traditional ECG interpretation primarily relies on the visual assessment of overt waveform characteristics by cardiologists. While this rule-based approach offers clear clinical interpretability,

---

†These authors contributed equally to this work.

it frequently fails to detect subtle fluctuations and complex patterns embedded within the signals, making it difficult to capture early, occult functional decline in the cardiovascular system[9,10].

In recent years, the rapid development of artificial intelligence (AI) technologies has provided novel perspectives to extract deeper insights from medical data[11–13]. In particular, deep learning algorithms have been proven capable of identifying high-dimensional, nonlinear features in ECG signals that are imperceptible to human vision[8,14–16]. Studies indicate that the heart is not merely a mechanical pump for blood circulation, but also a sensitive sensor of the body's overall physiological state, as its electrophysiological activities encode comprehensive information regarding human metabolism and autonomic nerve regulation[17–19]. Therefore, utilizing AI for the deep decoding of ECG signals can not only diagnose specific cardiac pathologies but also quantify an individual's biological aging, thereby driving a paradigm shift in medical applications from disease diagnosis to health assessment.

Based on this concept, and inspired by digital biomarkers and electrocardiomics[20–22], the concept of AI-ECG age has been proposed, which refers to the cardiac biological age inferred directly from raw ECG waveforms to characterize the overall functional reserve of the cardiovascular system[23–25]. In an ideal state of health, an individual's AI-ECG age should roughly align with their chronological age. However, for individuals with CVDs or those in a sub-optimal health state, accumulated physiological damage leads to the remodeling of cardiac electrophysiological characteristics[26], manifesting as an AI-ECG age significantly higher than the chronological age. This age gap represents more than a simple numerical deviation, but quantifies the degree of accelerated cardiac aging relative to chronological age and serves as a predictive biomarker reflecting an individual's cardiovascular health trajectory.

To more precisely capture the subtle, high-dimensional features associated with aging in ECG signals, this study developed a novel deep learning framework for AI-ECG age prediction. Specifically, we introduced ECGFounder[14], a universal pre-trained foundation model in the ECG domain. As an advanced foundation model pre-trained on over ten million clinical ECGs, ECG-Founder has proven highly effective in extracting complex and occult cardiac electrophysiological representations. Building upon this, the present study adopts a pre-training and full fine-tuning paradigm, leveraging its robust universal ECG representation capabilities to conduct efficient transfer learning for the task of cardiovascular physiological aging assessment. We developed and validated the algorithm within the UK Biobank (UKB) cohort[27] to evaluate whether the AI-ECG Age Gap can accurately reflect the underlying cardiac biological aging process. Furthermore, we systematically examined the independent prognostic efficacy of this metric in predicting major adverse cardiovascular and cerebrovascular events (MACCE) and various secondary clinical outcomes, exploring its broad application potential for non-invasive, low-cost cardiovascular health screening and personalized risk management in the general population..

Methods

Data Sources and Processing

Data Sources. This study utilized the UKB, a large-scale prospective biomedical database that recruited over 500,000 participants from across the United Kingdom, providing rich genetic, physiological, and medical record data. The UKB cohort includes multiple assessment phases, comprising an initial assessment (2006-2010) and subsequent repeat assessments and imaging visits, enabling long-term tracking of participants' health trajectories. In this study, raw waveform data of standard 12-lead ECGs were extracted by parsing the XML format files provided by the UKB, encompassing a total of 67,824 ECG records from 63,512 participants. The corresponding

calendar age was calculated from the birth year (Field 34) and birth month (Field 52) provided by the UKB, with the birth date uniformly set to the 15th of the respective month.

ECG Signal Preprocessing. To eliminate environmental noise during signal acquisition and extract high-quality electrophysiological features, all ECG signals sequentially underwent a standardized three-step filtering process. First, a 50 Hz notch filter was applied to eliminate powerline electromagnetic interference. Second, a 0.67–40 Hz bandpass filter was used to retain relevant ECG waveforms and filter out high-frequency noise. Finally, a median filter was utilized to remove baseline wander. Subsequently, all signals were subjected to Z-score normalization to eliminate inter-individual baseline differences and accelerate the convergence of subsequent deep learning models.

Study Population and Data Splitting. The data flow and screening process of the study population are illustrated in Figure 1. To construct a precise AI-ECG age prediction model and validate its clinical prognostic value, we divided the total dataset into a Development Cohort and a Clinical Evaluation Cohort. For the Development Cohort, we applied strict exclusion criteria at the participant level. (1) Participants with multiple ECG records due to multiple assessment visits were excluded to ensure the integrity of labels of the training data and prevent data leakage. (2) Participants already diagnosed with circulatory system diseases (defined based on UKB Category 2409), diabetes, or dyslipidemia at the time of ECG recording were excluded. This ensured that the model was trained on physiological signals from healthy individuals, thereby better capturing the electrophysiological characteristics of the natural aging process. After the aforementioned screening, the remaining healthy participants constituted the final Development Cohort and were randomly split in a 7:1:2 ratio into a Training Set, a Validation Set for hyperparameter tuning, and a Test Set for internal performance evaluation. In the Clinical Evaluation Cohort, to validate the predictive efficacy of the AI-ECG Age Gap as a digital biomarker in a broader population, participants excluded from the development cohort under criterion (2) due to pre-existing cardiovascular or metabolic diseases were directly included in this cohort.

Ethical Statement. The UKB obtained ethical approval from the North West Multi-centre Research Ethics Committee (REC reference: 21/NW/0157). All participants included in the UKB provided informed consent for their data to be used in health-related research. This study was conducted under UKB application number 90018.

Model Development

Model Architecture. The AI-ECG age prediction model in this study is based on ECGFounder[14], a universal ECG foundation model pre-trained on a massive dataset of over ten million ECGs. This large-scale pre-training enables the model to learn universal latent space representations of cardiac electrophysiological activities. The architecture of ECGFounder is built upon RegNet (RegNet-1d)[28,29], employing a multi-stage design that comprises a series of convolutional blocks with Group Convolutions and Channel-wise Attention Mechanisms. This design allows the model to not only capture the fine temporal fluctuations of ECG signals (temporal dependency) but also effectively integrate the spatial correlations across different leads (spatial dependency). This characteristic is crucial for identifying the subtle electrophysiological remodeling associated with cardiac aging. In this study, we employed a Transfer Learning strategy to conduct Full Fine-tuning on ECGFounder for the age prediction task (Figure 2). Specifically, we initialized the model with pre-trained weights, removed the original linear layer for diagnostic classification, and replaced it with a randomly initialized linear output layer dedicated to the regression task. During the full fine-tuning process, we trained the entire network end-to-end, updating not only the newly added regression layer but also allowing the pre-trained backbone network parameters to undergo adaptive updates, thereby precisely transferring the universal ECG feature space to

Figure 1: Flowchart of study population screening and cohort construction. Participants from the UK Biobank dataset were strictly screened and divided into a Development Cohort (healthy individuals for model training) and a Clinical Evaluation Cohort for prognostic

the cardiovascular physiological aging assessment task. The model inputs were standardized 12-lead ECG signals (sampling rate 500 Hz, duration 10 seconds), and the model weights were updated by minimizing the error between the predicted age and the calendar age.

Experimental Settings. The deep learning models in this study were constructed based on the PyTorch framework and trained on a single NVIDIA GeForce RTX 3090 GPU (24GB VRAM). We utilized the Adam optimizer (with parameters set to $\beta_1 = 0.9$, $\beta_2 = 0.999$) to perform full fine-tuning of the model for 10 epochs. To ensure training stability, the batch size was set to 256. Regarding learning rate scheduling, the initial learning rate was set to 3×10^{-3}, combined with a Cosine Annealing Decay strategy, capping the minimum learning rate during training at 1×10^{-5}. For model optimization and evaluation, this study directly adopted the Mean Absolute Error (MAE) as both the loss function and the primary evaluation metric, and the model with the lowest validation MAE was selected as the final model during the training process.

Model Interpretability. To investigate the internal decision-making mechanisms of the deep learning model when inferring biological age and to enhance its clinical transparency, this study employed saliency maps to visualize a representative case. Specifically, we selected a high-risk subject whose biological age was overestimated by the model. A corresponding saliency map was generated by computing the gradients of the model's predictive output with respect to the input ECG signals. Regions with higher gradient magnitudes indicate signal segments that contribute most significantly to the model's final prediction. To improve visualization quality and mitigate the influence of baseline noise, Gaussian smoothing was applied to the original saliency map.

Figure 2: Overall application flowchart and architecture of the AI-ECG age prediction model. The figure presents the clinical application pipeline and the model architecture. The prediction model was built upon the pre-trained ECGFounder and fully fine-tuned to predict chronological age.

Outcomes Definition and Clinical Value Assessment

Outcomes Definition. To comprehensively evaluate the clinical efficacy of AI-ECG age as a cardiovascular health biomarker, this study prespecified multi-level clinical endpoints within the UK Biobank cohort. (1) Primary Endpoint: Defined as Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), which is a composite endpoint. (2) Secondary Endpoints: Specific major cardiovascular and cerebrovascular events, including Coronary Heart Disease (CHD), Heart Failure, Stroke, and Atrial Fibrillation, were analyzed separately as secondary endpoints. Additionally, Hypertension and Diabetes were included as supplementary cardiometabolic outcomes. The determination of all disease outcomes was based on the International Classification of Diseases, Tenth Revision (ICD-10) codes. For heart failure, CHD, Hypertension, and Diabetes, only the first diagnosed event was recorded, while outcomes for atrial fibrillation and stroke were derived from algorithmically defined criteria.

Assessment Strategy. We quantified the degree of individual physiological aging by calculating the AI-ECG Age Gap, defined as the difference between the AI-predicted age and the actual calendar age (Gap = Age-AI - Age-Calendar). To validate its prognostic value, we incorporated the Age Gap into the analysis using the following two strategies. (1) Continuous Variable Analysis: We treated the AI-ECG Age Gap as a continuous variable to evaluate the linear or non-linear effects of each 1-unit increase in this metric on the risk of future adverse clinical events. (2) Categorical Variable Analysis: For clinical risk stratification, participants were divided into different risk groups. Using 6 years as the threshold, the population was categorized into an underestimation group (Gap < -6 years), a correct prediction group (-6 years $\leq$ Gap ≤ 6 years), and an overestimation group (Gap > 6 years). With the correct prediction group serving as the reference baseline, the relative risks of the underestimation and overestimation groups were calculated in comparison to individuals with normal physiological aging.

Statistical Analysis

All data processing and statistical analyses were performed in the R (version 4.2.2) and Python (version 3.11) environments. The main R packages used included survival and survminer for survival analysis, and rms for spline regression modeling. All statistical tests were two-sided, and a P-value < 0.05 was considered statistically significant.

Descriptive Statistics and Model Performance. For the baseline characteristics of the study population, continuous variables were expressed as mean $\pm$ standard deviation (Mean $\pm$ SD), while categorical variables were reported as frequencies and percentages (N, %). To quantify the accuracy and consistency of the AI-ECG age prediction model, we calculated the Pearson Correlation Coefficient (r) and Mean Absolute Error (MAE) between the predicted age and the actual calendar age.

Survival Analysis and Risk Assessment. This study utilized Cox Proportional Hazards Models to evaluate the strength of the association between the AI-ECG Age Gap and MACCE, as well as various secondary endpoints, with results presented as Hazard Ratios (HRs) and their 95% Confidence Intervals (CIs). To intuitively demonstrate the potential non-linear dose-response relationship between the Age Gap and clinical risks, we applied Restricted Cubic Splines (RCS) for fitting. Based on the risk stratification (underestimation, normal, overestimation), we plotted Kaplan-Meier survival curves to visualize the cumulative event incidence across different groups and employed the Log-rank Test to compare the statistical significance of differences among the groups. Survival time was defined as the period from the participant's baseline assessment to the occurrence of the endpoint event or the end of the follow-up period (December 31, 2022).

Covariate Adjustment Strategy. To strictly control the impact of potential confounding factors on the prognostic analysis, we constructed two multivariable adjustment models. Model 1 served as the basic adjustment model and primarily adjusted for demographic characteristics including age, sex, ethnicity, and body mass index. Model 2 further incorporated smoking status and pre-existing clinical comorbidities, including hypertension, diabetes, dyslipidemia, and chronic kidney disease, in addition to the variables included in Model 1.

Results

Study Population

In this study, we developed and evaluated the AI-ECG age prediction model based on the UKB dataset. The detailed baseline clinical characteristics of participants in each study cohort are summarized in Table 1. Initially, a total of 67,824 standard 12-lead ECG records from 63,512 participants were extracted from the overall dataset. Based on predefined criteria for independence and health status, the study population was divided into two subsets, the Development Cohort and the Clinical Evaluation Cohort.

After excluding individuals with multiple ECG measurement records, as well as those with a history of circulatory system diseases (based on UKB Category 2409), diabetes, or dyslipidemia at the time of measurement, a total of 26,871 healthy subjects (corresponding to 26,871 single ECG records) were included in the Development Cohort. This cohort was subsequently randomly divided into a training set (N = 18,809), a validation set (N = 2,687), and a test set (N = 5,375) in a 7:1:2 ratio. The validation set was used for hyperparameter fine-tuning during model training, while the hold-out test set was used to evaluate the baseline performance of the AI-ECG model in age prediction.

Subjects who were excluded during the screening phase of the development cohort due to a history of cardiovascular or metabolic diseases were all included in the Clinical Evaluation Cohort.

This cohort ultimately comprised 40,953 ECG records from 36,641 participants. Encompassing a broad spectrum of samples ranging from sub-optimal health to diagnosed diseases, this cohort was specifically utilized to evaluate the predictive value of the AI-ECG Age Gap for future cardiovascular clinical outcomes.

Table 1: Characteristics of the Study Cohorts

Characteristics	Development cohort (N = 26,871)	Evaluation cohort (N = 40,953)
Age (years)	63.94 (7.64)	67.11 (7.69)
Sex	N=26,871	N=40,953
Male	11,182 (41.61%)	21,655 (52.88%)
Female	15,689 (58.39%)	19,298 (47.12%)
Race	N=26,865	N=40,939
White	25,949 (96.59%)	39,377 (96.18%)
Asian	346 (1.29%)	676 (1.65%)
Black	179 (0.67%)	337 (0.82%)
Mixed	168 (0.62%)	195 (0.47%)
Others	223 (0.83%)	354 (0.86%)
BMI (kg/m^2)	25.69 (4.09)	27.13 (4.60)
Hypertension	0 (0%)	20,866 (50.95%)
Diabetes	0 (0%)	3,948 (9.64%)
Dyslipidemia	0 (0%)	16,303 (39.81%)
Chronic kidney disease	189 (0.70%)	1,306 (3.19%)
Smoking status	N=20,250	N=31,864
Non-smoker	19,544 (96.51%)	30,807 (96.68%)
Current smoking	706 (3.49%)	1,057 (3.32%)
Heart Failure	0 (0%)	530 (1.29%)
Atrial fibrillation	0 (0%)	2,403 (5.87%)
Myocardial infarction	0 (0%)	1,652 (4.03%)
Stroke	1 (0.00%)	793 (1.94%)
Coronary heart disease	0 (0%)	4,355 (10.63%)
MACCE	1 (0.00%)	5,017 (12.25%)
Follow-up time (years)	2.86 (2.70)	2.77 (2.57)

Performance of the AI-ECG Age Prediction Model

To quantify the prediction accuracy of the deep learning model fine-tuned on ECGFounder, we evaluated the consistency between the AI-ECG predicted age and the subjects' actual calendar age in the model development set (test set) and the clinical evaluation cohort, respectively. The results demonstrated that in the development cohort consisting of healthy subjects, the AI-ECG predicted age exhibited a linear correlation with the true calendar age, with a Pearson correlation coefficient (r) of 0.646 and a Mean Absolute Error (MAE) of 4.61 years. However, in the clinical evaluation cohort, the Pearson correlation coefficient decreased to 0.555, and the MAE correspondingly increased to 5.44 years. This discrepancy is expected because the

clinical evaluation cohort broadly included subjects with cardiovascular or metabolic diseases, ₂₃₅ and the accelerated physiological aging induced by these pathological states causes their AI-ECG ₂₃₆ predicted age to deviate significantly from their calendar age. This provided the foundation for ₂₃₇ subsequently utilizing the AI-ECG Age Gap to assess clinical risks. ₂₃₈

AI-ECG Age Gap as a Continuous Predictor of Cardiovascular Events ₂₃₉

We employed Cox proportional hazards models to evaluate whether the AI-ECG age gap as a ₂₄₀ continuous variable was independently associated with future adverse cardiovascular events. ₂₄₁ Detailed results are presented in Table 2. In the basic adjustment model (Model 1, adjusted ₂₄₂ for age, sex, ethnicity, and BMI), each 1-year increase in the AI-ECG Age Gap was associated ₂₄₃ with a significant 13% increase in the risk of the primary endpoint, MACCE (HR = 1.13, 95% CI: ₂₄₄ 1.11-1.15, p < 0.005). Furthermore, an increase in this metric was significantly associated with ₂₄₅ all predefined secondary clinical endpoints (all p < 0.005), with specific hazard ratios as follows: ₂₄₆ CHD (HR = 1.14), Heart Failure (HR = 1.15), Stroke (HR = 1.15), and Atrial Fibrillation (HR = ₂₄₇ 1.16). Notably, accelerated cardiac aging not only increased the risk of organic heart diseases ₂₄₈ but was also significantly associated with an elevated risk of cardiometabolic diseases such as ₂₄₉ Hypertension (HR = 1.19) and Diabetes (HR = 1.16). In Model 2, we further adjusted for smoking ₂₅₀ history and pre-existing comorbidities, including hypertension, diabetes, dyslipidemia, and chronic ₂₅₁ kidney disease. The results demonstrated that the independent predictive value of the AI-ECG ₂₅₂ Age Gap remained highly robust. The hazard ratios for the primary endpoint MACCE and heart ₂₅₃ failure were maintained at 1.13 (95% CI: 1.11-1.14) and 1.15 (95% CI: 1.12-1.18), respectively, ₂₅₄ and the statistical significance for all follow-up endpoints remained unchanged (all p < 0.001). ₂₅₅

Table 2: Association of AI-ECG Age Gap as a Continuous Variable with the Risk of Adverse Clinical Outcomes

Outcomes	Model 1		Model 2	
	HR (95% CI)	p-value	HR (95% CI)	p-value
MACCE	1.13 (1.11-1.15)	< 0.001	1.13 (1.11-1.14)	< 0.001
Coronary heart disease	1.14 (1.12-1.15)	< 0.001	1.14 (1.12-1.16)	< 0.001
Heart failure	1.15 (1.12-1.18)	< 0.001	1.15 (1.12-1.18)	< 0.001
Stroke	1.15 (1.12-1.19)	< 0.001	1.15 (1.11-1.18)	< 0.001
Atrial fibrillation	1.16 (1.14-1.18)	< 0.001	1.16 (1.14-1.18)	< 0.001
Hypertension	1.19 (1.17-1.20)	< 0.001	-	-
Diabetes	1.16 (1.14-1.19)	< 0.001	-	-

Model 1 adjusted for age, sex, race, and BMI.

Model 2 adjusted for age, sex, race, BMI, smoking, hypertension, diabetes, dyslipidemia, and chronic kidney disease.

    To visually illustrate the potential non-linear dose-response relationship between the AI-ECG ₂₅₆ Age Gap and the risk of clinical events, we plotted Restricted Cubic Spline (RCS) curves for ₂₅₇ Model 1, as shown in Figure 3. The RCS curves clearly indicate that as the AI-ECG Age Gap ₂₅₈ progressively widened, the relative risk of incident MACCE and various cardiovascular outcomes ₂₅₉ exhibited a continuous and significant upward trend. ₂₆₀

Figure 3: Restricted Cubic Spline (RCS) curves for the association between AI-ECG Age Gap and the risk of adverse clinical outcomes. The curves (adjusted for Model 1 covariates) demonstrate a continuous non-linear upward trend in the relative risk of MACCE and secondary cardiovascular outcomes as the continuous age gap widens.

Risk Stratification Based on AI-ECG Age Gap Classification

To evaluate the clinical utility of the AI-ECG Age Gap for risk stratification, participants were categorized into three groups using a threshold of ± 6 years: Underestimation ($\mathrm{Gap} < -6$), Correct Prediction ($-6 \leq \mathrm{Gap} \leq 6$), and Overestimation ($\mathrm{Gap} > 6$). The Correct Prediction group served as the reference baseline in Cox regression analyses to estimate relative risks, with results shown in Table 3.

Table 3: Risk of Adverse Clinical Outcomes Stratified by AI-ECG Age Gap Categories

Outcomes	Overestimation		Underestimation	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Model 1				
MACCE	4.57 (3.50-5.96)	< 0.001	0.46 (0.39-0.53)	< 0.001
Coronary heart disease	4.48 (3.40-5.90)	< 0.001	0.42 (0.35-0.50)	< 0.001
Heart failure	5.31 (3.29-8.56)	< 0.001	0.39 (0.30-0.50)	< 0.001
Stroke	4.54 (2.62-7.86)	< 0.001	0.41 (0.30-0.57)	< 0.001
Atrial fibrillation	3.73 (2.61-5.33)	< 0.001	0.39 (0.32-0.47)	< 0.001
Hypertension	7.10 (5.85-8.63)	< 0.001	0.34 (0.30-0.38)	< 0.001
Diabetes	6.62 (4.83-9.06)	< 0.001	0.45 (0.36-0.56)	< 0.001
Model 2				
MACCE	4.51 (3.46-5.89)	< 0.001	0.46 (0.40-0.54)	< 0.001
Coronary heart disease	4.40 (3.25-7.45)	< 0.001	0.42 (0.35-0.50)	< 0.001
Heart failure	5.17 (3.21-8.32)	< 0.001	0.39 (0.30-0.50)	< 0.001
Stroke	4.46 (2.57-7.72)	< 0.001	0.43 (0.31-0.59)	< 0.001

| Atrial fibrillation | 3.66 (2.56-5.23) | < 0.001 | 0.39 (0.32-0.47) | < 0.001 |

Model 1 adjusted for age, sex, race, and BMI.

Model 2 adjusted for age, sex, race, BMI, smoking, hypertension, diabetes, dyslipidemia, and chronic kidney disease.

In the basic adjustment model (Model 1), the overestimation group exhibited an extremely high risk for adverse prognoses. Specifically, the risk of developing the primary endpoint MACCE in the overestimation group was 4.57 times that of the normal group (HR = 4.57, 95% CI: 3.50-5.96, p < 0.001). Regarding secondary outcomes, the risk of organic heart diseases in the overestimation group also showed a precipitous increase, including CHD (HR = 4.48), Heart Failure (HR = 5.31), Stroke (HR = 4.62), and Atrial Fibrillation (HR = 3.73) (all p < 0.005). In addition, the risk of incident cardiometabolic diseases in this population surged, with the risks of Hypertension and Diabetes reaching 7.10 times and 6.62 times those of the normal population, respectively. In stark contrast, the underestimation group demonstrated significant protective characteristics across all clinical endpoints. Its risk of MACCE decreased by 54% (HR = 0.46, 95% CI: 0.39-0.53, p < 0.005), and the risk of developing other cardiovascular outcomes also generally declined by more than 50% (all p < 0.005).

In Model 2, the risk stratification results remained highly robust. The relative risks for MACCE (HR = 4.51, 95% CI: 3.46-5.89) in the overestimation group continued to be extremely high. Similarly, the risks for other secondary outcomes, including CHD, Heart Failure, Stroke, and Atrial Fibrillation, remained significantly elevated. Conversely, the MACCE risk in the underestimation group (HR = 0.46, 95% CI: 0.40-0.54) remained significantly lower than that of the normal population, with consistent protective effects observed across all secondary endpoints (all p < 0.005). This demonstrates that the AI-ECG Age Gap provides an additive risk predictive value independent of traditional clinical comorbidities.

Finally, we plotted Kaplan-Meier survival curves (Figure 4) to visually display the cumulative event incidence rates among different AI-ECG Age Gap groups during the follow-up period. The results revealed that the risk trajectories of the different groups gradually diverged over long-term follow-up; the cumulative incidence curve for the overestimation group exhibited a significantly steeper upward trend, while the curve for the underestimation group remained consistently flatter and situated below that of the normal group. This clear risk stratification pattern further bolstered the clinical utility of the AI-ECG Age Gap as a potential indicator for risk stratification.

Model Interpretability Analysis

To investigate the internal decision-making process of the deep learning model in physiological age prediction, we visualized the 12-lead ECG and its corresponding SmoothGrad saliency map for a representative case (Figure 5). The subject was a 55-year-old female with an AI-predicted age of 66 years, resulting in an Age Gap of +11 years. In the saliency map, red regions indicate positive attribution features that drive the model to increase the predicted age, whereas blue regions represent negative attribution features that drive the model to decrease the predicted age.

Furthermore, tightly aligned and alternating red–blue attribution bands were observed along the ascending and descending slopes of the QRS complexes as well as around their peaks and troughs. This pattern further demonstrated the model's extreme sensitivity to subtle morphological shifts during the ventricular depolarization process.

The visualization revealed that the model did not allocate attention randomly across the background baseline. Instead, it concentrated high attribution weights on heartbeat-related regions across all leads, particularly the QRS complexes and the preceding P wave phases, with notable contributions also present around the T waves. These findings suggest that the model primarily relies on electrophysiological events during cardiac depolarization and repolarization

Figure 4: Kaplan-Meier survival curves for cumulative event incidence stratified by AI-ECG Age Gap. The curves display diverging risk trajectories: the overestimation group (Gap > 6 years) exhibits a significantly steeper upward trend for adverse events, whereas the underestimation group (Gap < -6 years) demonstrates protective characteristics.

to infer biological age. Furthermore, the presence of tightly aligned, alternating red and blue   310
attribution bands indicated that the model did not depend on a single coarse feature but was   311
highly sensitive to subtle morphological shifts during depolarization and repolarization.   312

Discussion   313

This study developed and validated a deep learning framework for accurately assessing cardiac   314
biological age based on the large-scale pre-trained ECG foundation model ECGFounder. The   315
results demonstrate that the AI-ECG Age Gap not only effectively quantifies the degree of   316
individual cardiac aging but also exhibits excellent independent prognostic value in predicting   317
major adverse cardiovascular and cerebrovascular events (MACCE) and cardiometabolic diseases   318
as a non-invasive and convenient digital biomarker.   319

   By adopting a pre-training and fine-tuning paradigm, this study leveraged the universal electro-   320
physiological representations learned by ECGFounder from over ten million ECGs, significantly   321
enhancing the feature extraction efficiency for specific tasks. The introduction of the foundation   322
model enabled the accurate capture of subtle, aging-related electrophysiological remodeling even   323
with a relatively limited sample size, thereby achieving robust predictions of cardiac biological   324
age. In the experimental results, the AI-ECG predicted age and the actual chronological age   325
showed a good linear correlation in the development set (r=0.646, MAE = 4.61 years). However,   326
the correlation strength was moderate rather than strong, and certain prediction errors remained.   327
We speculate that this is because the participants in the UK Biobank cohort are predominantly   328
concentrated between 50 and 69 years old. This uneven age distribution may lead to systematic   329
biases when the model predicts populations, thereby amplifying the age deviation in the clinical   330

Figure 5: SmoothGrad saliency map of a representative high-risk case. Positive (red) and negative (blue) attribution features highlight the model's primary focus on the P wave, QRS complex, and T wave, reflecting its sensitivity to subtle morphological shifts during cardiac depolarization and repolarization.

cohort. On the other hand, in the clinical evaluation set, the correlation coefficient decreased to 0.555, and the MAE increased to 5.44 years. This validates the core hypothesis of this study that pathophysiological processes accelerate cardiac aging in populations with cardiovascular or metabolic diseases. Despite the presence of distributional biases, the AI-ECG Age Gap still demonstrated a robust association with the risk of future cardiovascular events. After adjusting for age, sex, BMI, smoking history, and pre-existing comorbidities (Model 2), each 1-year increase in the Age Gap was still associated with a significant 13% increase in the risk of incident MACCE. Categorical analysis further confirmed that when the AI-ECG age exceeded the chronological age by more than 6 years, the risk of MACCE was 4.57 times that of the normal population. This indicates that the aging information embedded in ECG signals captures occult cardiovascular functional degradation that is often missed in routine clinical assessments. The strong association of the overestimation group with incident Hypertension (HR = 7.10) and Diabetes (HR = 6.62) suggests that the remodeling of cardiac electrophysiological characteristics often precedes the overt clinical manifestations of organic lesions. Conversely, the underestimation group exhibited significant protective characteristics.

Through saliency map analysis, this study unveils the pathophysiological basis behind the model's decision-making. The attention assigned to the P wave captures age-related atrial electrical remodeling, which serves as the primary pathological substrate for arrhythmias such as atrial fibrillation[30]. The high attribution within the QRS complex reflects diffuse myocardial fibrosis and degenerative changes in the conduction system that alter ventricular depolarization[31].

Furthermore, the model's sensitivity to the T wave corresponds to repolarization abnormalities induced by slowed cardiomyocyte metabolism and declined autonomic nervous regulation[32]. The model's ability to acutely capture and amplify these early, subclinical micro-morphological changes on seemingly normal individual ECGs confirms that the AI-ECG age is a true reflection of the structural and functional evolution of the heart, rather than a mere result of data fitting.

As a digital biomarker, the AI-ECG age aims to quantify the biological aging status of an individual's heart and can serve as a surrogate marker for vascular health. Compared to traditional assessments based on single risk factors, this metric is derived directly from the comprehensive electrophysiological features embedded in raw ECG signals, possessing distinct interpretability and holism. From a clinical translation perspective, AI-ECG age prediction relies solely on routine ECG examinations, offering advantages such as low cost, non-invasiveness, high reproducibility, and high accessibility, thus exhibiting substantial real-world application potential. This tool can be integrated into existing routine physical examination workflows or primary care screening systems to efficiently assist in identifying high-risk individuals in the subclinical stage, thereby providing robust decision support for the preemptive prevention, early intervention, and precise risk stratification of cardiovascular diseases. However, this study still has certain limitations. First, the development cohort was primarily sourced from the UK Biobank, where participants are predominantly of European descent. The model's generalizability across populations with different ethnic and genetic backgrounds requires further validation. Second, addressing the prediction bias caused by the uneven age distribution observed in this study, future algorithms still need optimization. For instance, incorporating a distribution-aware loss function to mitigate regression shift caused by sample imbalance[33], or adopting a post-hoc statistical calibration strategy to align the distribution of predicted values[34,35], could enhance the prediction consistency and accuracy across the entire age spectrum. Furthermore, future studies should integrate longitudinal follow-up data with multi-omics profiling to characterize the biological mechanisms underlying cardiac electrical aging acceleration and to evaluate the feasibility of AI-ECG age as a metric for assessing the effectiveness of lifestyle interventions.

Despite these limitations, the present study provides strong evidence that AI-ECG age, as a highly scalable and non-invasive digital biomarker, possesses exceptional potential in the cardiovascular and cardiometabolic risk stratification of broad populations. With the continuous advancement of artificial intelligence technologies and the increasing adoption of electrocardiographic monitoring devices, AI-ECG age is expected to become a core tool in next-generation digital preventive cardiology, providing crucial support for the formulation of public health strategies and clinical decision-making.

Acknowledgments

This work is supported by the National Natural Science Foundation of China (62102008, 62172018), CCF-Tencent Rhino-Bird Open Research Fund (CCF-Tencent RAGR20250108), CCF-Zhipu Large Model Innovation Fund (CCF-Zhipu202414), PKU-OPPO Fund (BO202301, BO202503), Research Project of Peking University in the State Key Laboratory of Vascular Homeostasis and Remodeling (2025-SKLVHR-YCTS-02).

Competing interests

The authors declare no competing interests.

References

1. Naghavi, M., Ong, K.L., Aali et al. (2024). Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the global burden of disease study 2021. The Lancet *403*, 2100–2132. URL: http://dx.doi.org/10.1016/S0140-6736(24)00367-2. doi: 10.1016/s0140-6736(24)00367-2.

2. Stark, B.A., DeCleene, N.K., Desai et al. (2025). Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. JACC *86*, 2167–2243. URL: http://dx.doi.org/10.1016/j.jacc.2025.08.015. doi: 10.1016/j.jacc.2025.08.015.

3. World Health Organization (2025). Cardiovascular diseases (cvds) fact sheet. . URL: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).

4. Brauer, M., Roth, G.A., Aravkin et al. (2024). Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the global burden of disease study 2021. The Lancet *403*, 2162–2203. URL: http://dx.doi.org/10.1016/S0140-6736(24)00933-4. doi: 10.1016/s0140-6736(24)00933-4.

5. van Daalen, K.R., Zhang, D., Kaptoge et al. (2024). Risk estimation for the primary prevention of cardiovascular disease: considerations for appropriate risk prediction model selection. The Lancet Global Health *12*, e1343–e1358. URL: http://dx.doi.org/10.1016/S2214-109X(24)00210-9. doi: 10.1016/s2214-109x(24)00210-9.

6. Krittanawong, C., Rogers, A.J., Johnson et al. (2020). Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management. Nature Reviews Cardiology *18*, 75–91. URL: http://dx.doi.org/10.1038/s41569-020-00445-9. doi: 10.1038/s41569-020-00445-9.

7. Iyngkaran, P., Appuhamilage, P.Y., Patabandige et al. (2024). Barriers to cardiac rehabilitation among patients diagnosed with cardiovascular diseases—a scoping review. International Journal of Environmental Research and Public Health *21*, 339. URL: http://dx.doi.org/10.3390/ijerph21030339. doi: 10.3390/ijerph21030339.

8. Siontis, K.C., Noseworthy, P.A., Attia et al. (2021). Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. Nature Reviews Cardiology *18*, 465–478. URL: http://dx.doi.org/10.1038/s41569-020-00503-2. doi: 10.1038/s41569-020-00503-2.

9. Yang, K., Hong, M., Zhang, J. et al. (2025). Ecg-lm: Understanding electrocardiogram with a large language model. Health Data Science *5*. URL: http://dx.doi.org/10.34133/hds.0221. doi: 10.34133/hds.0221.

10. Huang, S., Zhang, D., Fan, S. et al. (2025). Opportunistic screening of wolff-parkinson-white syndrome using single-lead ai-ecg mobile system a real-world study of over 3.5 million ecg recordings in china. arXiv preprint arXiv:2510.24750.

11. Zhao, Q., Geng, S., Wang, B. et al. (2024). Deep learning in heart sound analysis: From techniques to clinical applications. Health Data Science *4*. URL: http://dx.doi.org/10.34133/hds.0182. doi: 10.34133/hds.0182.

12. Huang, S., Xing, W., Geng, S. et al. (2025). Combining ecg foundation model and xg-boost to predict in-hospital malignant ventricular arrhythmias in ami patients. arXiv preprint arXiv:2510.17172.

13. Zhang, S., Mu, W., Dong, D. et al. (2023). The applications of artificial intelligence in digestive system neoplasms: A review. Health Data Science *3*. URL: `http://dx.doi.org/10.34133/hds.0005`. doi: `10.34133/hds.0005`.

14. Li, J., Aguirre, A.D., Junior, V.M. et al. (2025). An electrocardiogram foundation model built on over 10 million recordings. NEJM AI *2*. URL: `http://dx.doi.org/10.1056/aioa2401033`. doi: `10.1056/aioa2401033`.

15. Tao, Y., Zhang, D., Pang, N. et al. (2024). Multi-modal artificial intelligence algorithm for the prediction of left atrial low-voltage areas in atrial fibrillation patient based on sinus rhythm electrocardiogram and clinical characteristics: a retrospective, multicentre study. European Heart Journal - Digital Health *6*, 200–208. URL: `http://dx.doi.org/10.1093/ehjdh/ztae095`. doi: `10.1093/ehjdh/ztae095`.

16. Fiorina, L., Carbonati, T., Narayanan, K. et al. (2025). Near-term prediction of sustained ventricular arrhythmias applying artificial intelligence to single-lead ambulatory electrocardiogram. European Heart Journal *46*, 1998–2008. URL: `http://dx.doi.org/10.1093/eurheartj/ehaf073`. doi: `10.1093/eurheartj/ehaf073`.

17. Ziegler, K.A., Engelhardt, S., Carnevale, D. et al. (2025). Neural mechanisms in cardiovascular health and disease. Circulation Research *136*, 1233–1261. URL: `http://dx.doi.org/10.1161/CIRCRESAHA.125.325580`. doi: `10.1161/circresaha.125.325580`.

18. Bao, X., Zhang, Z., Shen, Y. et al. (2025). Cardiovascular information and health engineering medicine. Research *8*. URL: `http://dx.doi.org/10.34133/research.0956`. doi: `10.34133/research.0956`.

19. Ritchie, R.H., and Abel, E.D. (2020). Basic mechanisms of diabetic heart disease. Circulation Research *126*, 1501–1525. URL: `http://dx.doi.org/10.1161/CIRCRESAHA.120.315913`. doi: `10.1161/circresaha.120.315913`.

20. Nie, G., Zhao, Q., Tang, G. et al. (2025). Artificial intelligence-derived photoplethysmography age as a digital biomarker for cardiovascular health. Communications Medicine *5*. URL: `http://dx.doi.org/10.1038/s43856-025-01188-9`. doi: `10.1038/s43856-025-01188-9`.

21. Zhang, D., Li, J., Geng, S. et al. (2026). ECGomics an open platform for AI-ECG digital biomarker discovery. arXiv preprint arXiv:2601.15326.

22. Chen, H., Cao, Z., Zhang, J. et al. (2025). Accelerometer-measured physical activity and neuroimaging-driven brain age. Health Data Science *5*. URL: `http://dx.doi.org/10.34133/hds.0257`. doi: `10.34133/hds.0257`.

23. Lima, E.M., Ribeiro, A.H., Paixão, G.M.M. et al. (2021). Deep neural network-estimated electrocardiographic age as a mortality predictor. Nature Communications *12*. URL: `http://dx.doi.org/10.1038/s41467-021-25351-7`. doi: `10.1038/s41467-021-25351-7`.

24. Cho, S., Eom, S., Kim, D. et al. (2024). Artificial intelligence–derived electrocardiographic aging and risk of atrial fibrillation: a multi-national study. European Heart Journal *46*, 839–852. URL: `http://dx.doi.org/10.1093/eurheartj/ehae790`. doi: `10.1093/eurheartj/ehae790`.

25. Hempel, P., Ribeiro, A.H., Vollmer, M. et al. (2025). Explainable ai associates ecg aging effects with increased cardiovascular risk in a longitudinal population study. npj Digital Medicine *8*. URL: `http://dx.doi.org/10.1038/s41746-024-01428-7`. doi: `10.1038/s41746-024-01428-7`.

26. Attia, Z.I., Friedman, P.A., Noseworthy, P.A. et al. (2019). Age and sex estimation using artificial intelligence from standard 12-lead ecgs. Circulation: Arrhythmia and Electrophysiology *12*. URL: `http://dx.doi.org/10.1161/CIRCEP.119.007284`. doi: `10.1161/circep.119.007284`.

27. Sudlow, C., Gallacher, J., Allen, N. et al. (2015). Uk biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLOS Medicine *12*, e1001779. URL: `http://dx.doi.org/10.1371/journal.pmed.1001779`. doi: `10.1371/journal.pmed.1001779`.

28. He, K., Zhang, X., Ren, S. et al. (2016). Deep residual learning for image recognition. In Proceedings of the IEEE conference on computer vision and pattern recognition. pp. 770–778.

29. Hong, S., Xu, Y., Khare, A. et al. (2020). Holmes: Health online model ensemble serving for deep learning models in intensive care units. pp. 1614–1624. URL: `http://dx.doi.org/10.1145/3394486.3403212`. doi: `10.1145/3394486.3403212`.

30. Magnani, J.W., Williamson, M.A., Ellinor, P.T. et al. (2009). P wave indices: Current status and future directions in epidemiology, clinical, and research applications. Circulation: Arrhythmia and Electrophysiology *2*, 72–79. URL: `http://dx.doi.org/10.1161/CIRCEP.108.806828`. doi: `10.1161/circep.108.806828`.

31. Lakatta, E.G., and Levy, D. (2003). Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: Part i: Aging arteries: A "set up" for vascular disease. Circulation *107*, 139–146. URL: `http://dx.doi.org/10.1161/01.cir.0000048892.83521.58`. doi: `10.1161/01.cir.0000048892.83521.58`.

32. Chen, P.S., Chen, L.S., Fishbein, M.C. et al. (2014). Role of the autonomic nervous system in atrial fibrillation: Pathophysiology and therapy. Circulation Research *114*, 1500–1515. URL: `http://dx.doi.org/10.1161/CIRCRESAHA.114.303772`. doi: `10.1161/circresaha.114.303772`.

33. Nie, G., Tang, G., and Hong, S. (2025). Dist loss: Enhancing regression in few-shot region through distribution distance constraint. In The Thirteenth International Conference on Learning Representations. URL: `https://openreview.net/forum?id=YeSxbRrDRl`.

34. Le Goallec, A., Diai, S., Collin, S. et al. (2022). Using deep learning to predict abdominal age from liver and pancreas magnetic resonance images. Nature Communications *13*. URL: `http://dx.doi.org/10.1038/s41467-022-29525-9`. doi: `10.1038/s41467-022-29525-9`.

35. Le, T.T., Kuplicki, R.T., McKinney, B.A. et al. (2018). A nonlinear simulation framework supports adjusting for age when analyzing brainage. Frontiers in Aging Neuroscience *10*. URL: `http://dx.doi.org/10.3389/fnagi.2018.00317`. doi: `10.3389/fnagi.2018.00317`.

16